BMS-986012 in Relapsed/Refractory SCLC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

November 14, 2014

Primary Completion Date

December 21, 2022

Study Completion Date

December 22, 2022

Conditions
Small Cell Lung Cancer
Interventions
BIOLOGICAL

BMS-986012 (anti-fucosyl-GM1)

BIOLOGICAL

Nivolumab

Trial Locations (16)

2065

Local Institution - 0020, St Leonards

3168

Local Institution - 0002, Clayton

4000

Local Institution - 0012, Liège

4102

Local Institution - 0011, Brisbane

9000

Local Institution - 0015, Ghent

10065

Local Institution - 0004, New York

27157

Local Institution - 0021, Winston-Salem

27710

Local Institution - 0001, Durham

T6G 1Z2

Local Institution - 0003, Edmonton

B3H 2Y9

Local Institution - 0017, Halifax

L8V 5C2

Local Institution - 0019, Hamilton

N6A 4L6

Local Institution - 0010, London

M5G 2M9

Local Institution - 0007, Toronto

6525 GA

Local Institution - 0013, Nijmegen

00927

Local Institution - 0009, San Juan

03080

Local Institution - 0008, Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02247349 - BMS-986012 in Relapsed/Refractory SCLC | Biotech Hunter | Biotech Hunter